看多
Interesting chart, possible breakout
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
“The fact is that if traders really believed that anything could happen at any time, there would be considerably fewer losers and more consistent winners.”
― Mark Douglas, Trading in the Zone
― Mark Douglas, Trading in the Zone
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
“The fact is that if traders really believed that anything could happen at any time, there would be considerably fewer losers and more consistent winners.”
― Mark Douglas, Trading in the Zone
― Mark Douglas, Trading in the Zone
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。